

CITATION REPORT

List of articles citing

A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma

DOI: 10.1097/01.ju.0000148261.19532.2c
Journal of Urology, 2005, 173, 48-51.

Source: <https://exaly.com/paper-pdf/39167874/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
449	Predicting outcomes in renal cell carcinoma. 2005 , 15, 289-97		43
448	Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. 2005 , 104, 511-20		194
447	[When is aftercare useful in renal cell cancer?]. 2005 , 44, 1018, 1020-3		1
446	Gene expression profiling predicts survival in conventional renal cell carcinoma. 2006 , 3, e13		154
445	Do patients benefit from intact specimen removal during laparoscopic radical nephrectomy?. 2005 , 2, 470-471		0
444	Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. 2005 , 11, 5128-39		123
443	Pathological features of renal neoplasms classified by size and symptomatology. <i>Journal of Urology</i> , 2006 , 176, 1317-20; discussion 1320	2.5	100
442	External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. <i>Journal of Urology</i> , 2006 , 175, 1235-9	2.5	113
441	Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. <i>Journal of Urology</i> , 2006 , 175, 46-52	2.5	86
440	Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , 2006 , 176, 1354-61; discussion 1361-2	2.5	165
439	Primer: using decision analysis to improve clinical decision making in urology. 2006 , 3, 439-48		11
438	Editorial Comment. <i>Journal of Urology</i> , 2006 , 176, 1337-1338	2.5	10
437	A survey of follow-up practice of urologists across Britain and Ireland following nephrectomy for renal cell carcinoma. 2006 , 61, 854-60; discussion 861-2		9
436	Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. 2006 , 68, 287-91		25
435	Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. 2006 , 68, 518-22		29
434	Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 224-30	2.8	
433	Bibliography. Current world literature. Renal immunology and pathology. 2006 , 15, 321-7		

432	Bibliography. Current world literature. Bladder cancer. 2006 , 16, 386-9		
431	Staging refinements in renal cell carcinoma. 2006 , 16, 317-20		8
430	A case for screening for renal cancer. <i>BJU International</i> , 2006 , 97, 220-1	5.6	9
429	Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. <i>BJU International</i> , 2006 , 98, 1228-32	5.6	29
428	Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. <i>European Urology</i> , 2006 , 49, 666-74	10.2	50
427	Tumor size improves the accuracy of TNM predictions in patients with renal cancer. <i>European Urology</i> , 2006 , 50, 521-8; discussion 529	10.2	50
426	Precystectomy nomogram for prediction of advanced bladder cancer stage. <i>European Urology</i> , 2006 , 50, 1254-60; discussion 1261-2	10.2	125
425	The pathology of renal epithelial neoplasms. 2006 , 33, 534-43		109
424	The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. 2006 , 106, 304-12		55
423	Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. 2006 , 107, 2604-8		45
422	Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. 2006 , 24, 3101-6		195
421	Update on the epidemiology and biology of renal cortical neoplasms. 2006 , 20, 975-85		15
420	Are nomograms better than currently available stage groupings for bladder cancer?. 2006 , 24, 3819-20		122
419	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. 2007 , 109, 4679-85		264
418	Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. 2007 , 7, 847-62		32
417	What is the prognostic value of the pT3a tumor classification for renal cell carcinoma?. 2007 , 4, 540-1		
416	Multi-institutional validation of a new renal cancer-specific survival nomogram. 2007 , 25, 1316-22		387
415	Costimulation, coinhibition and cancer. 2007 , 7, 15-30		79

414	Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. 2007 , 39, 459-65		68
413	Predicting cancer-control outcomes in patients with renal cell carcinoma. 2007 , 17, 295-302		10
412	Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. 2007 , 31, 1089-93		50
411	Predicting outcomes in patients with urologic cancers. 2007 , 1, 153-68		2
410	Kidney cancer: past, present, and future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 188-95	2.8	22
409	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. 2007 , 8, 304-10		324
408	TNM staging system for renal-cell carcinoma: current status and future perspectives. 2007 , 8, 554-8		70
407	[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]. 2007 , 46, 1371-2, 1374, 1376-8		3
406	Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. <i>Journal of Urology</i> , 2007 , 177, 477-80	2.5	68
405	Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?. <i>Journal of Urology</i> , 2007 , 177, 1682-6	2.5	32
404	Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy. 2007 , 41, 191-7		21
403	A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. <i>Journal of Urology</i> , 2007 , 178, 418-24; discussion 423-4	2.5	44
402	[Sporadic kidney cancer in patients younger than 45]. <i>Progres En Urologie</i> , 2007 , 17, 934-8	0.9	2
401	Re: prognostic nomogram for renal insufficiency after radical or partial nephrectomy. M. Sorbellini, M. W. Kattan, M. E. Snyder, A. A. Hakimi, D. M. Sarasohn and P. Russo <i>J Urol</i> 2006; 176: 472-476. <i>Journal of Urology</i> , 2007 , 177, 1201; author reply 1202-3	2.5	1
400	Imaging of kidney cancer. 2007 , 45, 119-47		40
399	Grading systems in renal cell carcinoma. <i>Journal of Urology</i> , 2007 , 177, 430-6	2.5	94
398	A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. <i>Journal of Urology</i> , 2007 , 178, 429-34	2.5	177
397	Pathology of adult renal parenchymal cancers. 17-37		

396	Post-treatment surveillance of renal cancer. 185-202		1
395	Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. <i>BJU International</i> , 2007 , 99, 77-80	5.6	90
394	Prognostic factors in localized renal cell cancer. <i>BJU International</i> , 2007 , 99, 1212-6	5.6	8
393	Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. <i>European Urology</i> , 2007 , 51, 722-9; discussion 729-31	10.2	76
392	p16INK4a expression and clinicopathologic parameters in renal cell carcinoma. <i>European Urology</i> , 2007 , 51, 732-7; discussion 738	10.2	14
391	Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. <i>European Urology</i> , 2007 , 51, 1616-24	10.2	77
390	A review on follow-up strategies for renal cell carcinoma after nephrectomy. <i>European Urology</i> , 2007 , 51, 1490-500; discussion 1501	10.2	75
389	Key clinical issues in renal cancer: a challenge for proteomics. <i>World Journal of Urology</i> , 2007 , 25, 537-564		25
388	[Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]. 2007 , 46, 636-41		
387	Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population. 2007 , 39, 699-703		4
386	Adjuvant therapy for high-risk renal cell carcinoma patients. 2007 , 8, 19-30		26
385	Risk stratification and prognostication of renal cell carcinoma. <i>World Journal of Urology</i> , 2008 , 26, 115-254		36
384	The changing face of renal cell carcinoma pathology. 2008 , 10, 235-44		6
383	Adjuvant therapy for renal cell carcinoma. 2008 , 10, 245-52		10
382	Nachsorge beim Nierenzellkarzinom. 2008 , 14, 1032-1039		
381	Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. 2008 , 113, 450-60		74
380	Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma. 2008 , 113, 477-83		18
379	Prognostic factors and selection for clinical studies of patients with kidney cancer. 2008 , 65, 235-62		60

378	Organ-confined clear cell renal cell carcinoma: the prognostic impact of microvascular invasion, nuclear grade and tumour size. 2008 , 116, 1027-33		5
377	Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. 2008 , 21, 1-6		73
376	Reclassification of the current tumor, node, metastasis staging in pT3 renal cell carcinoma. 2008 , 15, 582-6		8
375	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. <i>BJU International</i> , 2008 , 101 Suppl 4, 31-5	5.6	12
374	The use of positron-emission tomography in the diagnosis of tumour phenotype. <i>BJU International</i> , 2008 , 101 Suppl 4, 36-8	5.6	14
373	Prognostic models and algorithms in renal cell carcinoma. 2008 , 35, 613-25; vii		63
372	Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. <i>Journal of Urology</i> , 2008 , 180, 99-103; discussion 103	2.5	37
371	Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. 2008 , 72, 359-63		36
370	Prognostic factors for renal cell carcinoma. 2008 , 34, 407-26		16
369	The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma. 2008 , 7, 63-70		1
368	Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. <i>Journal of Urology</i> , 2008 , 180, 1284-9	2.5	32
367	Renal mass biopsy--a renaissance?. <i>Journal of Urology</i> , 2008 , 179, 20-7	2.5	301
366	External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2008 , 180, 1290-5; discussion 1295-6	2.5	32
365	Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. <i>Journal of Urology</i> , 2008 , 179, 1719-26	2.5	125
364	Molecular imaging of renal cell carcinoma. 2008 , 35, 605-11; vi		5
363	Mathematical models for prognostic prediction in patients with renal cell carcinoma. 2008 , 80, 113-23		40
362	Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. 2008 , 14, 1775-81		27
361	Which pathological features of renal cell carcinoma have the greatest prognostic value?. 2008 , 5, 74-5		

360	Targeted therapies in the treatment of renal cell carcinoma. 2008 , 15, 1166-74	4
359	Surgical and Medical Treatment. 377-399	
358	The staging of renal cell carcinoma. 2008 , 18, 455-61	7
357	Small renal masses: incidental diagnosis, clinical symptoms, and prognostic factors. 2008 , 310694	16
356	Radiologic evaluation of small renal masses (II): posttreatment management. 2008 , 918050	1
355	Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. <i>Current Oncology</i> , 2009 , 16,	2.8 2
354	Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. 2009 , 101, 1175-82	28
353	Renal Cell Carcinoma. 2009 ,	3
352	Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. 2009 , 83, 306-10	11
351	Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. 2009 , 27, 746-53	164
350	Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. 2009 , 18, 894-900	133
349	Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. 2009 , 114, 415-9	19
348	Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. 2009 , 115, 2092-103	91
347	Prognostic models: from the fates to the future. 2009 , 115, 2028-30	3
346	Facteurs pronostiques des carcinomes ĩ cellulules rĩales aux stades localisĩ et mĩastatiques. 2009 , 11, 260-266	
345	[Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years]. 2009 , 48, 1075-83	14
344	The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic. 2009 , 63, 1734-8	5
343	Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience. 2009 , 16, 268-73	16

342	The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. <i>BJU International</i> , 2009 , 103, 165-70	5.6	58
341	Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. <i>BJU International</i> , 2009 , 103, 160-4	5.6	25
340	Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. <i>BJU International</i> , 2009 , 104, 942-6	5.6	23
339	Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients. 2009 , 70, 59-70		21
338	The use of partial nephrectomy in European tertiary care centers. 2009 , 35, 636-42		64
337	Patient and pathologic correlates with perioperative and long-term outcomes of laparoscopic radical nephrectomy. 2009 , 74, 635-40		13
336	Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. 2009 , 13, 1-8		18
335	[Local recurrence of renal tumors]. 2009 , 33, 603-8		1
334	Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification. <i>Journal of Urology</i> , 2009 , 181, 480-5; discussion 485	2.5	25
333	Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. <i>Journal of Urology</i> , 2009 , 182, 1287-93	2.5	56
332	Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. <i>Journal of Urology</i> , 2009 , 181, 1004-12; discussion 1012	2.5	80
331	Metastatic renal cell carcinoma risk according to tumor size. <i>Journal of Urology</i> , 2009 , 182, 41-5	2.5	137
330	Predicting cancer-control outcomes in patients with renal cell carcinoma. 2009 , 19, 247-57		20
329	Renal cell cancer: state of the art in adjuvant therapy. 2010 , 5, 242-50		1
328	A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. 2010 , 34, 1233-40		101
327	Factors affecting outcome in renal cell carcinoma. 2010 , 20, 355-60		6
326	Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. 2010 , 59, 687-95		37
325	Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer. <i>World Journal of Urology</i> , 2010 , 28, 103-9	4	7

324	Prognostic factors in renal cell carcinoma. <i>World Journal of Urology</i> , 2010 , 28, 319-27	4	113
323	Adjuvante postoperative Therapie beim Nierenzellkarzinom. 2010 , 16, 150-156		
322	Renal cell carcinoma: where will the state-of-the-art lead us?. 2010 , 12, 193-201		13
321	Reporting methods in studies developing prognostic models in cancer: a review. 2010 , 8, 20		135
320	Reporting performance of prognostic models in cancer: a review. 2010 , 8, 21		119
319	External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. <i>European Urology</i> , 2010 , 57, 102-9	10.2	113
318	Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. <i>European Urology</i> , 2010 , 58, 655-68	10.2	73
317	TNM staging for renal cell carcinoma: time for a new method. <i>European Urology</i> , 2010 , 58, 517-9; discussion 519-21	10.2	28
316	Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy. 2010 , 202, 174.e1-7		42
315	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). 2010 , 2, 85-91		1
314	Whole-body MRI in follow-up of patients with renal cell carcinoma. 2010 , 51, 581-9		20
313	Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?. 2010 , 10, 813-23		2
312	Differential diagnosis of renal tumours with clear cell histology. 2010 , 42, 374-83		50
311	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. 2010 , 1, 152-163		230
310	The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. <i>Journal of Urology</i> , 2010 , 183, 486-91	2.5	3
309	Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 183, 909-14	2.5	26
308	Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 184, 53-8	2.5	33
307	[Prognostic value of erythrocyte polyamines levels in renal cell carcinoma. Prospective study in 418 cases]. <i>Progres En Urologie</i> , 2010 , 20, 272-8	0.9	

306	[Recommendations Onco-Urology 2010: Kidney cancer]. <i>Progres En Urologie</i> , 2010 , 20 Suppl 4, S319-39	0.9	19
305	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. 2010 , 76, 513.e1-6		31
304	Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review. <i>Journal of Urology</i> , 2010 , 183, 460-6	2.5	17
303	Imaging techniques for the patient with renal cell carcinoma. 2011 , 31, 245-53		9
302	[What is the role of active surveillance for small renal masses?]. <i>Progres En Urologie</i> , 2011 , 21, 895-900	0.9	
301	Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma. 2011 , 27, 59-63		8
300	The role of surgery in the management of early-stage renal cancer. 2011 , 25, 737-52		19
299	Editorial comment. 2011 , 78, 559-60; author reply 560		
298	Reply. 2011 , 78, 560		
297	Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. 2011 , 78, 1101-6		70
296	The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 738-44	2.8	27
295	Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. 2011 , 52, 104-9		18
294	Prognostic variables and nomograms for renal cell carcinoma. 2011 , 18, 20-31		18
293	Kattan postoperative nomogram for renal cell carcinoma: predictive accuracy in a Japanese population. 2011 , 18, 194-9		7
292	Prognostic models for renal cell carcinoma recurrence: external validation in a Japanese population. 2011 , 18, 667-71		10
291	The post-operative pathological prognostic parameters of clear cell renal cell carcinoma in pT1a cases. 2011 , 61, 116-21		14
290	Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. <i>European Urology</i> , 2011 , 60, 644-61	10.2	224
289	Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival. 2011 , 137, 393-8		26

288	Survival after complete surgical resection of multiple metastases from renal cell carcinoma. 2011 , 117, 2873-82		272
287	The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. 2011 , 117, 5314-24		33
286	The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. 2011 , 7, 1223-35		74
285	Recent developments in kidney cancer. 2011 , 5, 195-203		7
284	Time to recurrence after nephrectomy as a predictor of cancer-specific survival in localized clear-cell renal cell carcinoma. 2011 , 86, 47-52		13
283	Predictive models for the practical management of renal cell carcinoma. 2012 , 9, 73-84		11
282	Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. 2012 , 106, 279-83		60
281	Prognostic nomogram for disease-free survival in patients with renal adenocarcinoma. 2012 , 88, 271-6		1
280	Risk Calculators. 2012 , 529-554		
279	Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. <i>Journal of Urology</i> , 2012 , 187, 418-23	2.5	35
278	Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2012 , 187, 834-9	2.5	22
277	Integration of surgery and systemic therapy for renal cell carcinoma. 2012 , 39, 211-31, vii		21
276	Pulmonary metastasectomy. 2012 , 22, 91-9, vii		21
275	C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. 2012 , 12, 337		18
274	Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. 2012 , 107, 1131-7		42
273	Radioimmunotherapy of Renal Cancer. 2012 , 663-668		
272	Neoadjuvant and adjuvant treatment of renal cell carcinoma. 2012 , 12, 765-76		14
271	Systemic adjuvant therapies in renal cell carcinoma. 2012 , 6, e18		6

270	Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. 2012 , 118, 4412-20		13
269	A review of integrated staging systems for renal cell carcinoma. <i>European Urology</i> , 2012 , 62, 303-14	10.2	63
268	Can the Kattan nomogram still accurately predict prognosis in renal cell carcinoma using the revised 2010 tumor-nodes-metastasis reclassification?. 2012 , 19, 773-6		3
267	Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. <i>BJU International</i> , 2012 , 110, E21-7	5.6	22
266	Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. <i>BJU International</i> , 2012 , 109, 1600-6	5.6	65
265	Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. <i>BJU International</i> , 2012 , 110, 956-60	5.6	25
264	Nuclear Medicine Therapy. 2013 ,		3
263	Preoperative prediction of malignant involvement of resected ureters in patients undergoing radical cystectomy for bladder cancer. 2013 , 20, 501-6		2
262	Prognostic nomograms to predict oncological outcome of thyroid cancers. 2013 , 98, 4768-75		26
261	Renal Cell Carcinoma. 2013 ,		3
260	Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. 2013 , 20, 2096-102		15
259	Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). <i>European Urology</i> , 2013 , 64, 172-7	10.2	61
258	Prognostic value of microvascular invasion in predicting survival in renal cell carcinoma. 2013 , 37, 504-12		5
257	Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. 2013 , 81, 1190-5		13
256	Radioimmunotherapy of Renal Cell Carcinoma. 2013 , 257-263		
255	Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. 2013 , 31, 187-94		166
254	Prognostic value of microvascular invasion in predicting survival in renal cell carcinoma. 2013 , 37, 504-512		1
253	[CCAFU Recommendations 2013: Renal cancer]. <i>Progres En Urologie</i> , 2013 , 23 Suppl 2, S177-204	0.9	20

252	Re: Significant variability in 10-year cumulative radiation exposure incurred on different surveillance regimens after surgery for pT1 renal cancers: yet another reason to standardize protocols?. <i>Journal of Urology</i> , 2013 , 190, 1711	2.5	
251	Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 407-162.5		226
250	Pathology of Renal Cell Carcinoma. 2013 , 23-41		1
249	Prognostic Factors for Localized Renal Cell Carcinoma. 2013 , 83-102		
248	Assessment of Oncologic Risk for Clinical Stage T1 Renal Tumors and the Emerging Role of Renal Mass Biopsy. 2013 , 105-118		
247	Radical Nephrectomy for Localized Renal Tumors: Optimum Oncological and Renal Functional Considerations. 2013 , 119-131		
246	A review of contemporary data on surgically resected renal masses--benign or malignant?. 2013 , 81, 707-13		55
245	Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. <i>Journal of Urology</i> , 2013 , 190, 37-43	2.5	8
244	Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients. 2013 , 26, 1144-9		8
243	Renal Cell Carcinoma [How Can We Predict its Outcomes in Clinical Practice?]. 2013 , 13, 63-70		
242	The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. 2013 , 37, 1490-504		448
241	Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. 2013 , 37, 1505-17		96
240	A preoperative prognostic model predicting recurrence-free survival for patients with kidney cancer. <i>Japanese Journal of Clinical Oncology</i> , 2013 , 43, 63-8	2.8	12
239	Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma. 2013 , 140, 500-5		22
238	Significant variability in 10-year cumulative radiation exposure incurred on different surveillance regimens after surgery for pT1 renal cancers: yet another reason to standardize protocols?. <i>BJU International</i> , 2013 , 111, 891-6	5.6	13
237	Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. 2013 , 37, 1160-7		33
236	Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. 2013 , 19, 3259-67		233
235	The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. 2013 , 7, E687-91		30

234	Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma. 2013 , 8, e59936		16
233	Recent developments in kidney cancer. 2013 , 5, 195		
232	Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. 2014 , e214-21		5
231	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. 2014 , 8, E398-412		25
230	Clinico-pathological analysis of renal cell carcinoma demonstrates decreasing tumour grade over a 17-year period. 2014 , 8, 125-32		6
229	Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. 2014 , 110, 2537-43		4
228	Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1277-84	2.8	40
227	Systematic lymph node dissection in lung metastasectomy of renal cell carcinoma: an 18 years of experience. 2014 , 109, 823-9		27
226	Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. <i>European Urology</i> , 2014 , 66, 936-48	10.2	109
225	Clinico-pathological prognostic factors of renal cell carcinoma: A 15-year review from a single center in Greece. 2014 , 6, 116-21		7
224	Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e23-8	2.8	19
223	Adjuvant therapy for renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 408-12	3.3	5
222	Renal cell carcinoma. 2014 , 349, g4797		311
221	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. 2014 , 120, 1059-67		100
220	Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. 2014 , 7, 369		8
219	[Organ and kidney function preservation in renal cell carcinoma]. 2014 , 53, 1329-43		
218	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). 2014 , 15, 404		46
217	The association between socioeconomic status, renal cancer presentation, and survival in the United States: a survival, epidemiology, and end results analysis. 2014 , 84, 583-9		16

216	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 43.e9-16	2.8	10
215	Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. <i>Journal of Urology</i> , 2014 , 192, 350-6	2.5	16
214	BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2014 , 191, 603-10	2.5	58
213	Neural network design for the recurrence prediction of post-operative non-metastatic kidney cancer patients. 2015 ,		1
212	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. 2015 , 16, 676-85		163
211	Prognostication in localised renal cell carcinoma. 2015 , 16, 603-4		6
210	Kidney Cancer. 2015 ,		1
209	Percutaneous biopsy for risk stratification of renal masses. 2015 , 7, 265-74		24
208	Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When?. 2015 , 33, 4131-3		5
207	Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser. 2015 , 21, 211-7		11
206	Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 225-30	3.3	17
205	Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. <i>Journal of Urology</i> , 2015 , 193, 1911-6	2.5	34
204	Clinicopathologic outcomes of cystic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 67-70	3.3	18
203	Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. 2015 , 49, 205-10		18
202	Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma. 2015 , 143, 492-9		3
201	Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. 2015 , 16, 743-9		24
200	Post partial nephrectomy surveillance imaging: an evidence-based approach. 2015 , 16, 23		3
199	Outcome prediction for patients with renal cell carcinoma. 2015 , 32, 172-83		24

198	Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma. 2015 , 22, 264-70		10
197	Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 499-502	2.8	12
196	Clinical utility of concurrent single-nucleotide polymorphism microarray on fresh tissue as a supplementary test in the diagnosis of renal epithelial neoplasms. 2015 , 144, 731-7		2
195	Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma. 2015 , 14, 141		10
194	Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort. <i>World Journal of Urology</i> , 2015 , 33, 381-8		13
193	C1-C2 pigmented villonodular synovitis and clear cell carcinoma: unexpected presentation of a rare disease and a review of the literature. 2015 , 24 Suppl 4, S465-71		7
192	Resection of Pancreas and Duodenum During Radical Nephrectomy: Analysis of A Single Center Experience. 2016 , 06,		
191	Mutations in the Mitochondrial ND1 Gene Are Associated with Postoperative Prognosis of Localized Renal Cell Carcinoma. 2016 , 17,		21
190	[CCAFU french national guidelines 2016-2018 on renal cancer]. <i>Progres En Urologie</i> , 2016 , 27 Suppl 1, S27-S51	0.9	12
189	Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. 2016 , 1, 272-281		18
188	Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. <i>Journal of Urology</i> , 2016 , 196, 58-9	2.5	
187	Introduction to small renal tumours and prognostic indicators. 2016 , 36, 495-503		11
186	[Urologic malignancies in renal transplant candidates and recipients]. <i>Progres En Urologie</i> , 2016 , 26, 1094-5		13 7
185	Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. <i>BJU International</i> , 2016 , 117, E60-6	5.6	9
184	Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. <i>BJU International</i> , 2016 , 117, E87-94	5.6	31
183	Erste randomisierte Phase-3-Studie zur adjuvanten Therapie mit einem Tyrosinkinaseinhibitor bei Hochrisiko-Nierenzellkarzinom. 2016 , 22, 886-888		
182	Surveillance following surgery for nonmetastatic renal cell carcinoma. 2016 , 26, 432-8		3
181	Guía de manejo del carcinoma de células renales. 2016 , 25, 169-189		0

180	Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. 2016 , 114, 375-9		25
179	The impact of three-dimensional tumor volume on cancer-specific survival for patients with pT1 clear-cell renal cell carcinoma. <i>World Journal of Urology</i> , 2016 , 34, 83-8	4	3
178	ACR Appropriateness Criteria Renal Cell Carcinoma Staging. 2016 , 13, 518-25		28
177	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. 2016 , 387, 2008-16		374
176	R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy. 2016 , 21, 367-372		15
175	A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. 2017 , 17, 9		17
174	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. 2017 , 18, 15		31
173	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. 2017 , 19, 14		36
172	Risk Assessment in Small Renal Masses: A Review Article. 2017 , 44, 189-202		3
171	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. <i>Journal of Urology</i> , 2017 , 198, 810-816	2.5	15
170	Systematic review of renal carcinoma prognostic factors. 2017 , 41, 215-225		
169	Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: A systematic review and meta-analysis. 2017 , 41, 70-77		28
168	Prognostic Significance of Macroscopic Appearance in Clear Cell Renal Cell Carcinoma and Its Metastasis-Predicting Model. 2017 , 67, 610-619		3
167	Risk models for patients with localized renal cell carcinoma. 2017 , 41, 564-570		
166	Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. 2017 , 28, 2747-2753		20
165	The utility of microRNAs as biomarkers in predicting progression and survival in patients with clear-cell renal cell carcinoma. <i>BJU International</i> , 2017 , 120, 305-307	5.6	1
164	Risk models for patients with localised renal cell carcinoma. 2017 , 41, 564-570		3
163	Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. 2017 , 14, 753-759		11

162	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. 2017 , 3, 913-920		78
161	Systematic review of renal carcinoma prognostic factors. 2017 , 41, 215-225		8
160	Online tools for patient counseling in bladder and kidney cancer-ready for prime time?. 2017 , 6, 1123-1131		
159	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. 2018 , 23, 540-555		42
158	Nonoperative Management of Spinal Epidural Abscess: Development of a Predictive Algorithm for Failure. 2018 , 100, 546-555		20
157	Renal Cell Carcinoma. 2018 , 225-236		
156	Clear cell carcinomas of the ovary and kidney: clarity through genomics. 2018 , 244, 550-564		27
155	Renal capsular invasion is a prognostic biomarker in localized clear cell renal cell carcinoma. 2018 , 8, 202		8
154	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018 , 36, 1943-1952	4	78
153	Prognostic and Predictive Factors for Renal Cell Carcinoma. 2018 , 13, 309-331		2
152	SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma. 2018 , 15, 4564-4570		15
151	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. 2018 , 4, 100-105		7
150	Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. <i>Journal of Urology</i> , 2018 , 199, 43-52	2.5	23
149	Introduction to T1 Renal Tumours and Prognostic Indicators. 2018 , 7-19		
148	Evaluation of microvascular invasion as a prognostic factor in the progression of non-metastatic renal cancer. <i>Central European Journal of Urology</i> , 2018 , 71, 386-390	0.9	1
147	Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment. 2018 , 2, 95-102		
146	Prognostication in Kidney Cancer: Recent Advances and Future Directions. 2018 , JCO2018790147		29
145	Traitement focal et traitement systématique dans la prise en charge du cancer du rein métastatique : une question de complémentarité 2018 , 105 Suppl 3, S221-S228		

144	[French ccAFU guidelines' Update 2018-2020: Management of kidney cancer]. <i>Progres En Urologie</i> , 2018 , 28 Suppl 1, R5-R33	0.9	1
143	Cancer du rein mEstatique : quels critEres de choix en 2e ligne ?. 2018 , 105 Suppl 3, S242-S254		
142	Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. <i>Current Oncology</i> , 2018 , 25, e444-e453	2.8	6
141	Urologic Pathology: Key Parameters from a Urologist's Perspective. 2018 , 11, 893-901		1
140	Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma. 2018 , 11, 5535-5544		36
139	Development of Predictive Algorithms for Pre-Treatment Motor Deficit and 90-Day Mortality in Spinal Epidural Abscess. 2018 , 100, 1030-1038		14
138	RETRACTED: Recommandations franEises du ComitE de CancEologie de l'AFU Actualisation 2018-2020: prise en charge du cancer du rein French ccAFU guidelines Update 2018-2020: Management of kidney cancer. <i>Progres En Urologie</i> , 2018 , 28, S3-S31	0.9	8
137	Follow-up after curative treatment of localised renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1953-1959	4	17
136	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. 2018 , 24, 4407-4415		29
135	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. 2018 , 17, 1355-1364		98
134	The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. 2018 , 70, 109-125		3
133	Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. 2019 , 74, 284-290		12
132	Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma. <i>BJU International</i> , 2019 , 123, 270-276	5.6	22
131	Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma. 2019 , 44, 3370-3376		2
130	2019 CUA Annual Meeting Abstracts. 2019 , 13,		
129	The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. 2019 , 17, 182		13
128	Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma. 2019 , 134, 148-153		5
127	Validation of the GGrade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. 2019 , 9, 13218		9

126	miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. 2019 , 3, 119-132		5
125	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. 2019 , 37, 2062-2071		45
124	Adjuvant therapy in renal cell carcinoma. 2019 , 125, 2935-2944		25
123	BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 510-518	2.8	2
122	Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. 2019 , 2019, 7309205		12
121	Postoperative prognostic model for patients with clear cell renal cell carcinoma in a Chinese population. 2019 , 26, 624-629		4
120	Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers. 2019 , 17, 371-377		18
119	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. 2019 , 26, 532-542		21
118	Is Chest Computed Tomography Always Necessary Following Nephrectomy for Renal Cell Carcinoma? A Pilot Study in Single Tertiary Institution. 2019 , 43, 333-337		1
117	Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?. 2019 , 43, 1249-1252		4
116	Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study. 2019 , 98, e14237		1
115	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. 2019 , 25, 1165-1173		10
114	Diagnosis and Surgical Management of Renal Tumors. 2019 ,		1
113	Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy. 2019 , 123, 174-180		9
112	UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. 2020 , 136, 162-168		7
111	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	1
110	The impact of TNFSF14 on prognosis and immune microenvironment in clear cell renal cell carcinoma. 2020 , 42, 1055-1066		5
109	CT and MR imaging surveillance of stage 1 renal cell carcinoma after microwave ablation. 2020 , 45, 2810-2824		4

108	[Retrovesical recurrence of renal cell carcinoma 14 years after laparoscopic nephrectomy: a case report]. 2020 ,		
107	T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis. <i>Frontiers in Oncology</i> , 2020 , 10, 579619	5.3	6
106	Current Role of Adjuvant Therapy in High Risk for Recurrence Resected Kidney Cancer. 2020 ,		
105	Are small renal masses all the same?. 2020 , 27, 439-447		4
104	Prognostic Effect of Comorbid Disease and Immune Gene Expression on Mortality in Kidney Cancer-A Population Based Study. <i>Cancers</i> , 2020 , 12,	6.6	2
103	[Follow-up of renal cell carcinoma based on stage and initial treatment]. 2020 , 59, 162-168		1
102	ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. 2020 , 482, 74-89		10
101	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. 2021 , 4, 473-482		7
100	Recurrent renal cell carcinoma presenting as a cutaneous metastasis: A case report and review of the literature. 2021 , 13, 174-176		0
99	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 1369-1376	4	7
98	Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries. 2021 , 11, 1479		5
97	Clinical features and prognostic factors of patients with metastatic renal cell carcinoma stratified by age. 2021 , 13, 8290-8305		4
96	Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis. <i>Frontiers in Oncology</i> , 2021 , 11, 630842	5.3	2
95	Predictive factors for disease recurrence in patients with locally advanced renal cell carcinoma treated with curative surgery. 2021 , 84, 405-409		3
94	A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases. 2021 , 2021, 6627562		3
93	Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study. 2021 , 9, e25635		2
92	A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. 2021 , 11, 8650		1
91	Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses. 2021 ,		0

90	Association of RGS20 expression with the progression and prognosis of renal cell carcinoma. 2021 , 22, 643		2
89	Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 80, 20-31	10.2	10
88	The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. 2021 , 11, 17822		3
87	Development and Validation of Prognostic Nomogram for Young Patients with Kidney Cancer. 2021 , 14, 5091-5103		
86	Development and validation of nomogram based on a novel platelet index score to predict prognosis in patients with renal cell carcinoma. 2021 , 12, 6301-6309		1
85	Kidney. 2010 , 479-489		17
84	Kidney. 2010 , 547-560		1
83	Pathology of Renal Cell Carcinoma. 2020 , 49-72		2
82	Malignant Renal Tumors. 2012 , 1413-1474.e33		25
81	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. 2020 , 16, e1264-e1271		5
80	Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4. 2017 , 18, 1225-1232		3
79	Staging of renal cell carcinoma: Current concepts. 2009 , 25, 446-54		21
78	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. 2020 , 61, 260-268		3
77	Prognostic Influence of Coagulative Tumor Necrosis and the Tumor Location for T1a Renal Cell Carcinoma. 2006 , 47, 456		2
76	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. 2017 , 49, 635-642		4
75	Use of the American Society of Anesthesiologists Classification as an Additional Planning Tool for Renal Cell Carcinoma Assessment. 2013 , 04, 7-14		1
74	Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review. 2021 ,		1
73	Korean Nomogram for the Prediction of Recurrence-free Survival after Definitive Surgery for Renal Cell Carcinoma. 2006 , 47, 963		

72 Section 6. **2007**, 171-224

71 Palliation in Renal Cancer. **2008**, 507-528

70 Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma. **2008**, 265-273

69 Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. **2009**, 367-403

68 Nierenzellkarzinom. **2009**, 331-369

67 Renal Cell Carcinoma: Clinical Presentation, Staging, and Prognostic Factors. **2012**, 69-88

66 Adjuvant Systemic Therapy for Renal Cell Carcinoma. **2012**, 173-186

65 Renal Neoplasia. **2012**, 1508-1535

64 Renal Carcinoma Surveillance Counterpoint: Canada. **2013**, 383-385

63 Postoperative Surveillance Protocols for Renal Cell Carcinoma. **2013**, 283-305

62 Surgical Approaches to Treatment of Renal Cell Carcinoma. **2013**, 699-711

61 Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. **2013**, 155-177

60 Outcomes: Prognostic Factors, Models, and Algorithms. **2013**, 323-333

59 Pathology of Renal Cell Carcinoma. **2013**, 51-69

1

58 Nierenzellkarzinom. **2014**, 347-397

57 Postoperative Nomogramme in der Nierentumorchirurgie. **2015**, 1-5

56 Independent Predictors of Clinical Outcomes and Prediction Models for Renal Tumor Pathology. **2015**, 355-371

55 Renal Cell Carcinoma: Clinical Presentation, Staging, and Prognostic Factors. **2015**, 105-121

1

- 54 Adjuvant Systemic Therapy for Renal Cell Carcinoma. **2015**, 229-243
- 53 Postoperative Nomogramme in der Nierentumorchirurgie. **2016**, 381-385
- 52 Overview and Staging of Renal Neoplasms. **2016**, 53-65
- 51 Analysis of NF- κ B and Clinical Prognostic Factors in Clear Cell Renal Cell Carcinoma. **2016**, 14, 63-68
- 50 Advisable Follow-Up for Kidney Tumors. **2017**, 1-13
- 49 Resection of Renal Cell Carcinoma Involving the Liver with Tumor Thrombus Extending into Inferior Vena Cava Requiring Venovenous Bypass. **2017**, 141-163
- 48 Adjuvant Therapy for High-Risk Renal Cell Carcinoma. **2019**, 263-269
- 47 Renal cell carcinoma. *Annals of Urologic Oncology*, **2018**, 1, 1-18 0.1 0
- 46 Advisable Follow-Up for Kidney Tumors. **2019**, 641-652
- 45 Renal kitle nedeniyle radikal nefrektomi yapılan hastaların tıbbi karakteristiklerinin değerlendirilmesi; 18 yıl sonucuları. *Sleyman Demirel Üniversitesi Tıp Fakültesi Dergisi*,
- 44 Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. **2020**, 411-435
- 43 Outcomes: Prognostic Factors, Models, and Algorithms. **2020**, 345-359
- 42 Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study (Preprint).
- 41 Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.. *Journal of Cancer Metastasis and Treatment*, **2021**, 7, 3.8 1
- 40 Postoperative Surveillance Protocols for Renal Cell Carcinoma. **2020**, 361-386
- 39 Prognostic Factors: Markers. **2008**, 53-67
- 38 Therapeutic Counseling for the Medical Management of Renal Cell Carcinoma. **2008**, 515-534
- 37 Comment prédire le risque dolutif chez les patients atteints d'un cancer du rein?. **2008**, 57-69

36 Nierenzellkarzinom. **2007**, 245-275

35 Nierenzellkarzinom. **2014**, 347-397

34 [French ccAFU guidelines - update 2020-2022: management of kidney cancer]. *Progres En Urologie*, **2020**, 30, S2-S51 0.9 3

33 Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. *Current Oncology*, **2009**, 16 Suppl 1, S60-6 2.8 6

32 The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma. *Canadian Journal of Urology*, **2016**, 23, 8151-4 0.8 12

31 Identification and validation of novel metastasis-related signatures of clear cell renal cell carcinoma using gene expression databases. *American Journal of Translational Research (discontinued)*, **2020**, 12, 4108-4126 3 4

30 [Predicting postoperative recurrence of stage I-III renal clear cell carcinoma based on preoperative CT radiomics feature nomogram]. *Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University*, **2021**, 41, 1358-1365 0.5

29 Neutrophil-to-Lymphocyte Ratio Predicts Cancer Outcome in Locally Advanced Clear Renal Cell Carcinoma.. *Clinical Genitourinary Cancer*, **2021**, 3.3 1

28 Partial nephrectomy and positive surgical margin, oncologic outcomes and predictors: a 15-year single institution experience.. *Central European Journal of Urology*, **2021**, 74, 516-522 0.9 1

27 Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association.. *Japanese Journal of Clinical Oncology*, **2022**, 2.8

26 Risk models for recurrence and survival after kidney cancer: a systematic review.. *BJU International*, **2021**, 5.6 3

25 Development and Validation of a CT-Based Radiomics Nomogram for Predicting Postoperative Progression-Free Survival in Stage I-III Renal Cell Carcinoma.. *Frontiers in Oncology*, **2021**, 11, 742547 5.3 0

24 Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.. *Cancers*, **2022**, 14, 6.6 2

23 External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 2.8 0

22 Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations.. *World Journal of Urology*, **2022**, 1 4

21 Acetylshikonin, A Novel CYP2J2 Inhibitor, Induces Apoptosis in RCC Cells via FOXO3 Activation and ROS Elevation.. *Oxidative Medicine and Cellular Longevity*, **2022**, 2022, 9139338 6.7 2

20 DataSheet_1.docx. **2020**,

19 DataSheet_2.zip. **2020**,

18	Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis.. <i>World Journal of Urology</i> , 2022 , 1	4	0
17	Ocular adnexal metastases from renal cell carcinoma: An update and comprehensive literature review. <i>Saudi Journal of Ophthalmology</i> , 2021 , 35, 209	0.9	
16	Re: Björk Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.03.006 . <i>European Urology</i> , 2022 ,	10.2	1
15	A Causal Framework for Making Individualized Treatment Decisions in Oncology. 2022 , 14, 3923		0
14	Postoperative Nomogramme in der Nierentumorchirurgie. 2022 , 1-3		0
13	Predicting Oncologic Outcomes in Small Renal Tumors. 2022 ,		1
12	Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation.		0
11	Hot topics in renal cancer pathology: implications for clinical management.		0
10	Adjuvant therapy options in renal cell carcinoma [targeting the metastatic cascade.		0
9	Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.		0
8	Development of a 3-MicroRNA Signature and Nomogram for Predicting the Survival of Patients with Uveal Melanoma Based on TCGA and GEO Databases. 2022 , 2022, 1-13		1
7	Markers of local kidney cancer recurrence: A surgeon's mistake or a pattern? Review. 039156032211409		0
6	The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. 2022 , 14, 6018		1
5	A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs). 13,		0
4	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. Volume 16, 49-64		0
3	Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. 2023 , 83, 441-451		0
2	Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database. 2023 , 13,		0
1	Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions.		0

